
2-Butoxyethyl 3-pyridinecarboxylate
Nicoboxil has been investigated for the treatment of Acute Low Back Pain, where it is typically considered an effective and safe therapeutic option. Nevertheless, it is predominantly found paired with nonivamide as a combination topical analgesic product where its proposed mechanism of action as a rubefacient is complementary and ultimately synergistic with nonivamide's capsaicin activity. Such combination topical analgesics are only available for purchase and use (for humans) in some parts of Europe and Asia, like Germany and Australia. Despite topical nicoboxil/nonivamide topical analgesic medication being used since the 1950s, recent studies demonstrate continued interest in the medication(s) given its demonstrated efficacy, safety, and capability to be used as an alternative musculoskeletal pain therapy option with less systemic side effects when compared to the oral non-steroidal anti-inflammatory drugs and opioids that may be more typically prescribed. — DrugBank
- IUPAC 名称
- 2-butoxyethyl pyridine-3-carboxylate
- 分子式
- C12H17NO3
- 分子量
- 223.27 g/mol
- 精确质量
- 223.12084340 Da
- XLogP3
- 2.1
- 拓扑极性表面积
- 48.4 Ų
- 氢键供体
- 0
- 氢键受体
- 4
- 共价单元
- 1
- 已定义的立体中心
- 0
又称
另有 16 个已报告名称
外部数据库标识符
- ChEBI:CHEBI:32322
- ChEMBL:CHEMBL2105161
- EPA DTXSID:DTXSID4057635
- PubMed:28008281
- PubMed:25929250
- PubMed:19588430
- PubMed:13825636
于 2026-08-31 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。